183 related articles for article (PubMed ID: 23990684)
21. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis.
de Fost M; Hollak CE; Groener JE; Aerts JM; Maas M; Poll LW; Wiersma MG; Häussinger D; Brett S; Brill N; vom Dahl S
Blood; 2006 Aug; 108(3):830-5. PubMed ID: 16527890
[TBL] [Abstract][Full Text] [Related]
22. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
Poll LW; vom Dahl S; Koch JA; Börner D; Willers R; Cohnen M; Jung G; Scherer A; Niederau C; Häussinger D; Mödder U
Rofo; 2001 Oct; 173(10):931-7. PubMed ID: 11588682
[TBL] [Abstract][Full Text] [Related]
23. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.
Stirnemann J; Boutten A; Vincent C; Mekinian A; Heraoui D; Fantin B; Fain O; Mentré F; Belmatoug N
Blood Cells Mol Dis; 2011 Jan; 46(1):34-8. PubMed ID: 21084203
[TBL] [Abstract][Full Text] [Related]
24. Scintigraphic evaluation of Tc-99m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease.
Lorberboym M; Vallabhajosula S; Lipszyc H; Pastores G
Clin Genet; 1997 Jul; 52(1):7-11. PubMed ID: 9272706
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
26. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
[TBL] [Abstract][Full Text] [Related]
27. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
28. Imaging and quantifying skeletal involvement in Gaucher disease.
Maas M; Poll LW; Terk MR
Br J Radiol; 2002; 75 Suppl 1():A13-24. PubMed ID: 12036829
[TBL] [Abstract][Full Text] [Related]
29. Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status.
Jaramillo D; Bedoya MA; Wang DJ; Pena AH; Delgado J; Jaimes C; Ho-Fung V; Kaplan P
AJR Am J Roentgenol; 2015 Jun; 204(6):1296-302. PubMed ID: 26001241
[TBL] [Abstract][Full Text] [Related]
30. Bone, bone marrow, and MIBI scintigraphic findings in Gaucher's disease "bone crisis".
Blocklet D; Abramowicz M; Schoutens A
Clin Nucl Med; 2001 Sep; 26(9):765-9. PubMed ID: 11507294
[TBL] [Abstract][Full Text] [Related]
31. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
[TBL] [Abstract][Full Text] [Related]
32. Bone involvement in Gaucher's disease: 'bone crisis' or disease complication?
La Civita L; Mariani G; Porciello G; Viacava P; Molea N; Lazzeri E; Pasero G; Ferri C
Clin Exp Rheumatol; 1996; 14(2):195-8. PubMed ID: 8737728
[TBL] [Abstract][Full Text] [Related]
33. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
34. Technetium-99m 2-methoxy-isobutyl-isonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: correlation with MRI and other prognostic factors.
Erten N; Saka B; Berberoglu K; Turkmen C; Unal S; Bakir B; Yekeler E; Besisik SK
Ann Hematol; 2007 Nov; 86(11):805-13. PubMed ID: 17684742
[TBL] [Abstract][Full Text] [Related]
35. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
[TBL] [Abstract][Full Text] [Related]
36. Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity.
Alexandrakis MG; Kyriakou DS; Passam FH; Malliaraki N; Vlachonikolis IG; Karkavitsas N
Hematol Oncol; 2003 Mar; 21(1):17-24. PubMed ID: 12605419
[TBL] [Abstract][Full Text] [Related]
37. 99mTc-MDP Bone Scintigraphy in Gaucher Disease.
Kesim S; Turoglu HT; Tutar E; Ozguven S; Erdil TY
Clin Nucl Med; 2020 Oct; 45(10):e455-e456. PubMed ID: 32604108
[TBL] [Abstract][Full Text] [Related]
38. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
39. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.
van Dussen L; Biegstraaten M; Dijkgraaf MG; Hollak CE
Orphanet J Rare Dis; 2014 Jul; 9():112. PubMed ID: 25056340
[TBL] [Abstract][Full Text] [Related]
40. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
